ADAP Advocacy, through its 340B Project, has released a new infographic that scrutinizes the 340B Drug Pricing Program. The infographic reinforces the message of a policy paper and commercial released earlier this year under the same title: “340B PROGRAM: The Glue That Should Hold Our Healthcare System Together.” The initiative questions whether the program is fulfilling its intended purpose.
Congress established the 340B Drug Pricing Program to extend federal resources and improve patient care. Later, the Affordable Care Act added requirements for hospitals to provide free care and financial aid to poor patients, known as charity care. However, ADAP Advocacy points out that charity care continues to decline year after year. Meanwhile, 340B drug purchases rose above $100 billion in 2025 across over 42,000 covered entities and more than 32,000 pharmacies. This disparity suggests that the program’s growth is not translating into better outcomes for vulnerable populations.
The infographic connects the dots on the program’s unfettered growth and how that growth is failing to deliver on the program’s promise. It continues ADAP Advocacy’s “340B Too Big To Fail” national advocacy campaign, highlighting hospitals’ declining charity, rising healthcare executive compensation, and exploding patient medical debt, among other issues. The infographic can be downloaded online at https://tinyurl.com/y6asjaw2.
For readers in the health industry, this development signals a growing scrutiny of the 340B program’s real-world impact. As drug purchases soar, the lack of corresponding charity care could indicate that hospitals are prioritizing revenue over patient assistance. This trend may lead to increased calls for transparency and reform, potentially affecting how covered entities operate and how patients access affordable medications. The rising medical debt among patients is particularly alarming, as it can deter individuals from seeking necessary care and worsen health disparities. ADAP Advocacy’s campaign underscores the need for stakeholders to ensure that the 340B program serves its original mission of improving access to care for underserved populations.
ADAP Advocacy’s mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improve access to care for persons living with HIV/AIDS. The organization works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration. This latest infographic is part of their effort to inform the public and policymakers about the 340B program’s shortcomings, which could influence future legislation and program oversight. As the debate over drug pricing and healthcare funding continues, the implications for patients, providers, and the pharmaceutical industry are significant.
